|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1998-2-19
|
|
pubmed:abstractText |
Ifosfamide and paclitaxel are antineoplastic agents with broad activity and with different mechanisms of action. A Phase I trial was conducted to determine the maximum tolerated dose and associated toxicities of these agents when used in combination.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
82
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
561-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9452275-Adult,
pubmed-meshheading:9452275-Aged,
pubmed-meshheading:9452275-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9452275-Breast Neoplasms,
pubmed-meshheading:9452275-Colonic Neoplasms,
pubmed-meshheading:9452275-Female,
pubmed-meshheading:9452275-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:9452275-Humans,
pubmed-meshheading:9452275-Ifosfamide,
pubmed-meshheading:9452275-Lung Neoplasms,
pubmed-meshheading:9452275-Male,
pubmed-meshheading:9452275-Mesna,
pubmed-meshheading:9452275-Middle Aged,
pubmed-meshheading:9452275-Neoplasms,
pubmed-meshheading:9452275-Neutropenia,
pubmed-meshheading:9452275-Ovarian Neoplasms,
pubmed-meshheading:9452275-Paclitaxel
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
|
|
pubmed:affiliation |
Hematology-Oncology Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
